Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis

Current Hematologic Malignancy Reports

Volumn 5, Issue 2, 2010, Pages 53-61

  Alchalby, Haefaa ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; JAK2 mutation; Myelofibrosis; Reduced intensity transplantation

Indexed keywords

BUSULFAN; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; CYTOGENETICS; GRAFT VERSUS HOST REACTION; HUMAN; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; REDUCED INTENSITY CONDITIONING; REMISSION; REVIEW; RISK ASSESSMENT; SPLENECTOMY; SPLENOMEGALY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRIMARY MYELOFIBROSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77954623805     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0044-z     Document Type: Review

References (51)

1. Tefferi A: Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005, 23(33):8520-8530.
2. Smith RE, Chelmowski MK, Szabo EJ: Myelofibrosis: a review of clinical and pathologic features and treatment. Crit Rev Oncol Hematol 1990, 10(4):305-314.
3. •• Mesa RA, Verstovsek S, Cervantes F, et al.: Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV myelofibrosis), post essential thrombocythemia myelofibrosis (post-ET myelofibrosis), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007, 31(6):737-740. This paper recommends a standardized, uniform terminology regarding myeloproliferative neoplasms.
4. • Cervantes F, Passamonti F, Barosi G: Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008, 22(5):905-914. This review addresses the recent data about survival and prognosis in myeloproliferative neoplasms.
5. • Kröger N, Mesa RA: Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008, 22(3):474-486. This review discusses in detail the current conventional treatment options and allogeneic stem cell transplantation for patients with myelofibrosis.
6. • Kerbauy DM, Gooley TA, Sale GE, et al.: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007, 13(3):355-365. Through its long follow-up (up to 15 years in some patients), this study confirms the curative potential of AHSCT in myelofibrosis.
7. Rajantie J, Sale GE, Deeg HJ, et al.: Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986, 67 (6):1693-1697.
8. Soll E, Massumoto C, Clift RA, et al.: Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995, 86(12):4667-4673.
9. Dokal I, Jones L, Deenmamode M, et al.: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1989, 71(1):158-160.
10. Creemers GJ, Lowenberg B, Hagenbeek A: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992, 82(4):772-773.
11. Guardiola P, Anderson JE, Bandini G, et al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93(9):2831-2838.
12. Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102 (12):3912-3918.
13. Ballen K, Sobocinski KA, Zhang MJ, et al.; the Chronic Leukemia Working Committee of the Center for International Blood Marrow Transplant Research: Outcome of Bone Marrow Transplantation for Myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 170.
14. Byrne JL, Beshti H, Clark D, et al.: Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol 2000, 108(2):430-433.
15. Cervantes F, Rovira M, Urbano-Ispizua A, et al.: Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000, 26(6):697-699.
16. Hessling J, Kroger N, Werner M, et al.: Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 119(3):769-772.
17. Devine SM, Hoffman R, Verma A, et al.: Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99(6):2255-2258.
18. Hertenstein B, Guardiola P, Finke J, et al.: Non-myeloablative (NMA) stem cell transplantation (SCT) for myeloid metaplasia with myelofibrosis (MMM): a survey from the Chronic Leukemia Working Party of the EBMT [abstract]. Blood (ASH Annual Meeting Abstracts) 2002, 100:Abstract 70.
19. Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105(10):4115-4119.
20. Kröger N, Zabelina T, Schieder H, et al.: Pilot study of reducedintensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005, 128(5):690-697.
21. Bacigalupo A, Dominetto A, Pozzi S, et al.: Allogeneic hemopoietic stem transplant for patients with idiopathic myelofibrosis using a reduced intensity thiotepa based conditioning regimen [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 684.
22. • Bacigalupo A, Soraru M, Dominietto A, et al.: Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2009 Aug 31 (Epub ahead of print). These authors developed a scoring system that can identify a group with a very poor outcome following AHSCT.
23. George B, Kerridge I, Gottlieb D, et al.: A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis. Bone Marrow Transplant 2008, 42 (8):567-568.
24. Kröger N, Holler E, Kobbe G, et al.: Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 683.
25. •• Kröger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2009, 114 (26):5264-5270. This prospective study with a large cohort of myelofibrosis patients (n=103) revealed a favorable outcome of allografting with reduced-intensity conditioning.
26. Merup M, Lazarevic V, Nahi H, et al.: Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006, 135(3):367-373.
27. Patriarca F, Bacigalupo A, Sperotto A, et al.: Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20- year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008, 93(10):1514-1522.
28. • Gupta V, Kröger N, Aschan J, et al.: A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 2009, 44(5):317-320. This work showed on a retrospective basis that AHSCT after reduced-intensity conditioning led to results comparable to those after myeloablative conditioning, with lower TRM in the elderly group.
29. Tefferi A, Mesa RA, Nagorney DM, et al.: Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000, 95(7):2226-2233.
30. Li Z, Deeg HJ: Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 2001, 15(3):465-467. (Pubitemid 32243782)
31. Li Z, Gooley T, Applebaum FR, Deeg HJ: Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001, 97(7):2180-2181. (Pubitemid 32239105)
32. Ciurea SO, Sadegi B, Wilbur A, et al.: Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008, 141(1):80-83.
33. Hussein K, Huang J, Lasho T, et al.: Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009, 82(4):255-259.
34. Tam CS, Abruzzo LV, Lin KI, et al.: The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009, 113(18):4171-4178.
35. Baurmann H, Burlakova I, Jedlickova Z, et al.: Allogeneic haematopoietic cell transplantation for myelofibrosis-Close post-transplant surveillance is mandatory [abstract V59]. Presented at the Corporate Annual Conference '09 of the German, Austrian, and Swiss Haematology and Oncology Societies. Mannheim/Heidelberg, Germany; October 2-6, 2009.
36. James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148. (Pubitemid 40663494)
37. Percy MJ, McMullin MF: The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol 2005, 23(3- 4):91-93.
38. •• Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22 (7):1299-1307. An excellent review of the recent available data regarding the clinical significance of JAK2V617F mutation and its allele burden in the nontransplant setting.
39. Ditschkowski M, Elmaagacli AH, Trenschel R, et al.: No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Biol Blood Marrow Transplant 2006, 12(12):1350-1351.
40. • Kröger N, Badbaran A, Holler E, et al.: Monitoring of the JAK2- V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109(3):1316-1321. The report describes the utility of a sensitive JAK2V617F assay for assessment of minimal residual disease after AHSCT for myelofibrosis.
41. Steckel NK, Koldehoff M, Ditschkowski M, et al.: Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007, 83(11):1518-1520.
42. Rumi E, Passamonti F, Arcaini L, et al.: Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant 2009 Sep 7 (Epub ahead of print).
43. Alchalby H, Badbaran A, Bock O, et al.: Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 2010 Jan 11 (Epub ahead of print).
44. Thiele J, Kvasnicka HM, Dietrich H, et al.: Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005, 20(3):879-889.
45. Sale GE, Deeg HJ, Porter BA: Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 2006, 12(12):1285-1294.
46. Benjamini O, Koren-Michowitz M, Amariglio N, et al.: Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008, 22(10):1961-1963.
47. • Kröger N, Alchalby H, Klyuchnikov E, et al.: JAK2-V617Ftriggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009, 113(8):1866-1868. This report compares salvage and preemptive DLI approaches for relapse management after AHSCT in myelofibrosis.
48. Dupriez B, Morel P, Demory JL, et al.: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88(3):1013-1018.
49. Cervantes F, Barosi G, Demory JL, et al.: Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998, 102(3):684-690.
50. Elliott MA, Verstovsek S, Dingli D, et al.: Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007, 31(11):1503-1509.
51. • Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895-2901. This is the most recent established scoring system, based on data from 1054 patients with PMF.